Abstract:Alport syndrome is a genetic disease caused by mutations in type IV collagen and is characterized by progressive kidney disease. The Col4 alpha 3(-/-) mouse model recapitulates the main features of human Alport syndrome. Previously, it was reported that kidney microRNA-21 (miR-21) expression is significantly increased in Col4 alpha 3(-/-) mice, and administration of anti-miR-21 oligonucleotides (anti-miR-21) attenuates kidney disease progression in Col4 alpha 3(-/-) mice, indicating that miR-21 is a viable therapeutic target for Alport syndrome. However, the expression pattern of miR-21 in the kidneys of patients with human Alport syndrome has not been evaluated. Paraffin-embedded kidney specimens were obtained from 27 patients with Alport syndrome and from 10 normal controls. They were evaluated for miR-21 expression and for in situ hybridization and mRNA expression by quantitative polymerase chain reaction. In addition, anti-miR-21 was administrated to Col4 alpha 3(-/-) mice at different stages of disease, and changes in proteinuria, kidney function, and survival were monitored. Transcriptomic analysis of mouse kidney was conducted using RNA sequencing. miR-21 expression was significantly elevated in kidney specimens from patients with Alport syndrome compared to normal controls. Elevated renal miR-21 expression positively correlated with 24 h urine protein, serum blood urea nitrogen, serum creatinine, and severity of kidney pathology. On histological evaluation, high levels of miR-21 were localized to damaged tubular epithelial cells and glomeruli. Kidney specimens from both humans and mice with Alport syndrome exhibited abnormal expression of genes involved in kidney injury, fibrosis, inflammation, mitochondrial function, and lipid metabolism. Administration of anti-miR-21 to Alport mice resulted in slowing of kidney function decline, partial reversal of abnormal gene expression associated with disease pathology, and improved survival. Increased levels of miR-21 in human Alport kidney samples showed a correlation with kidney disease severity measured by proteinuria, biomarkers of kidney function, and kidney histopathology scores. These human data, combined with the finding that a reduction of miR-21 in Col4 alpha 3(-/-) mice improves kidney phenotype and survival, support miR-21 as a viable therapeutic target for the treatment of Alport syndrome.

Establishment of Microrna, Transcript and Protein Regulatory Networks in Alport Syndrome Induced Pluripotent Stem Cells

Dysregulated Expression of Microrna-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome

Genetic diagnosis of Alport syndrome in 16 Chinese families

Pharmacological approach and diagnosis for Alport syndrome

Endoplasmic Reticulum Stress Activation in Alport Syndrome Varies Between Genotype and Cell Type

Generation and Characterization of an Integration-Free Ipsc Line SDUBMSi006-A from a Patient with Alport Syndrome Caused by COL4A3 Gene Mutations.

Investigation of exon skipping therapy in kidney organoids from Alport syndrome patients derived iPSCs

Genetic Reprogramming with Stem Cells Regenerates Glomerular Epithelial Podocytes in Alport Syndrome

Correlation Between Mrna Expression Level of the Mutant COL4A5 Gene and Phenotypes of XLAS Females.

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

mRNA Analysis Identifies deep Intronic Splicing Variants Leading to Alport Syndrome and Overcomes the Problem of Negative Results of Exome Sequencing

Establishment of the Induced Pluripotent Stem Cell Line (Nckdi005-A) from a Male Patient with Alport Syndrome Carrying a Homozygous Frameshift Mutation in the COL4A4 Gene.

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

A mouse model for X-linked Alport syndrome induced by Del-ATGG in the Col4a5 gene

[Features of Clinical Phenotype and Genotype in Alport Syndrome: a Monocentric Study].

Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome

iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome

Exploration of Gene Therapy for Alport Syndrome

A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome

A Novel Splicing Mutation Identified in a Chinese Family with X-linked Alport Syndrome Using Targeted Next-Generation Sequencing.

mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing